Psyence Biomed Announces Phase IIb Clinical Trial Listing on the Australian New Zealand Clinical Trials Registry (ANZCTR)

Psyence Biomedical Ltd announced its Phase IIb clinical trial for nature-derived psilocybin treatment in patients with Adjustment Disorder post-advanced cancer diagnosis, listed on ANZCTR. The trial, involving 84 patients, tests three psilocybin doses with psychotherapy, aiming for primary endpoint results by 2025.